OPT-302-1005 Coast Study (NCT04757636) – A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)
OPT-302-1004 Shore Study (NCT04757610) – A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)
RGX-314-2103 Bioreactor Study (NCT04832724) – A Phase 2, Open-label Study to Explore the Pharmacodynamics of Two Doses in Two Formulations of RGX-314 Gene Therapy Administered via Subretinal Delivery in Participants with Neovascular Age-related Macular Degeneration
RGX-314-2104 Atmosphere Study (NCT04704921) – A Randomized, Partially Masked, Controlled, Phase2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD
BP43445 Alluvium Study (NCT05151731)– A Phase II, Double Masked, Active Comparator Controlled Study to Investigate the Efficacy,Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7200220 Administered Intravitreally in Patients with Diabetic Macular Edema
OTT166-201 Dream Study (NCT05409235)- A Phase 2 Randomized, Double-Masked, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of OTT166 Ophthalmic Solution in the Treatment of Diabetic Retinopathy
GR44277 Meerkat Study (NCT05642312) – A Phase III, Randomized, Double-Masked, Sham-Controlled Study to Investigate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of RO7200220 Administered Intravitreally in Patients with Uveitic Macular Edema
GT005-02 Explore Study (NCT04437368) – A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005
Ionis Study Golden Study ISIS 696844 – CS5 (NCT03815825) – Phase 2, Randomized, Placebo-Controlled, Double-Masked Study (57 weeks) to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRX
ALXN2040-GA-201 Study (NCT05019521) – A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
CLNP023E12201 Study (NCT05230537) – A randomized, participant and investigator masked, placebo-controlled, multicenter, proof-ofconcept study to assess the safety and efficacy of LNP023 (Iptacopan) in patients with early and intermediate age-related macular degeneration